ENTRY       D11613                      Drug
NAME        Pegcetacoplan (JAN/USAN/INN);
            Empaveli (TN)
PRODUCT     EMPAVELI (Apellis Pharmaceuticals)
            SYFOVRE (Apellis Pharmaceuticals)
FORMULA     C170H248N50O47S4. (C2H4O)n
REMARK      Therapeutic category: 3999
            ATC code: L04AA54
            Product: D11613<JP/US>
EFFICACY    Complement inhibitor
  DISEASE   Paroxysmal nocturnal hemoglobinuria [DS:H01053]
COMMENT     Treatment of paroxysmal nocturnal hemoglobinuria (PNH), complement-mediated nephropathies, and age-related macular degeneration (AMD)
TARGET      C3 (C3b) [HSA:718] [KO:K03990]
  PATHWAY   hsa04610(718)  Complement and coagulation cascades
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA54 Pegcetacoplan
                  D11613  Pegcetacoplan (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Complement Inhibitors
                Pegcetacoplan
                 D11613  Pegcetacoplan (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D11613  Pegcetacoplan (JAN/USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Complement and coagulation
                C3 (C3b)
                 D11613  Pegcetacoplan (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11613
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11613
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11613
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11613
DBLINKS     CAS: 2019171-69-6
            PubChem: 405226480
///
